Targeting Apoptosis Pathways for New Cancer Therapeutics

被引：147

作者：

Bai, Longchuan ^{[1
]}

Wang, Shaomeng

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

来源：

ANNUAL REVIEW OF MEDICINE, VOL 65 | 2014年 / 65卷

基金：

美国国家卫生研究院;

关键词：

BCL-2; BCL-XL; XIAP; cIAPs; MDM2; p53; CHRONIC LYMPHOCYTIC-LEUKEMIA; SMALL-MOLECULE ANTAGONIST; KAPPA-B ACTIVATION; BCL-2; FAMILY; NAVITOCLAX ABT-263; P53; PATHWAY; CELL-DEATH; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MDM2; INHIBITOR;

D O I：

10.1146/annurev-med-010713-141310

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

The past decade has witnessed tremendous advances in the discovery and development of novel small-molecule inhibitors targeting apoptosis pathways for cancer treatment, with some compounds now in clinical development. Early promising clinical data have been reported with these new classes of anticancer drugs. This review highlights the recent advancements in the development of small-molecule inhibitors targeting three major classes of antiapoptotic proteins: antiapoptotic B cell lymphoma 2 (BCL-2) proteins, inhibitor of apoptosis proteins (IAPs), and murine double-minute 2 (MDM2). Special emphasis is given to those that have been advanced into clinical trials. The challenges and future directions in the further preclinical and clinical development of these new anticancer drugs are also discussed.

引用

页码：139 / 155

页数：17

共 99 条

[1]

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo [J].

Ackler, Scott ;

Mitten, Michael J. ;

Foster, Kelly ;

Oleksijew, Anatol ;

Refici, Marion ;

Tahir, Stephen K. ;

Xiao, Yu ;

Tse, Christin ;

Frost, David J. ;

Fesik, Stephen W. ;

Rosenberg, Saul H. ;

Elmore, Steven W. ;

Shoemaker, Alexander R. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (05) :869-880

[2]

An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737 [J].

Al-Harbi, Sayer ;

Hill, Brian T. ;

Mazumder, Suparna ;

Singh, Kamini ;

DeVecchio, Jennifer ;

Choudhary, Gaurav ;

Rybicki, Lisa A. ;

Kalaycio, Matt ;

Maciejewski, Jaroslaw P. ;

Houghton, Janet A. ;

Almasan, Alexandru .

BLOOD, 2011, 118 (13) :3579-3590

[3]

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism [J].

Allensworth, Jennifer L. ;

Sauer, Scott J. ;

Lyerly, H. Kim ;

Morse, Michael A. ;

Devi, Gayathri R. .

BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) :359-371

[4]

Amaravadi RK, 2013, J CLIN ONCOL, V31

[5]

Amaravadi RK, 2011, P ANN M AM ASS CANC

[6]

[Anonymous], J CLIN ONCOL S

[7]

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 [J].

Aziz, M. H. ;

Shen, H. ;

Maki, C. G. .

ONCOGENE, 2011, 30 (46) :4678-4686

[8]

A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer [J].

Baggstrom, Maria Q. ;

Qi, Yingwei ;

Koczywas, Marianna ;

Argiris, Athanassios ;

Johnson, Elizabeth A. ;

Millward, Michael J. ;

Murphy, Sara C. ;

Erlichman, Charles ;

Rudin, Charles M. ;

Govindan, Ramaswamy .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (10) :1757-1760

[9]

Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells [J].

Balakrishnan, Kumudha ;

Wierda, William G. ;

Keating, Michael J. ;

Gandhi, Varsha .

BLOOD, 2008, 112 (05) :1971-1980

[10]

MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].

BARAK, Y ;

JUVEN, T ;

HAFFNER, R ;

OREN, M .

EMBO JOURNAL, 1993, 12 (02) :461-468

← 1 2 3 4 5 6 7 8 9 10 →